CAPRICOR THERAPEUTICS INC. - COMMON STOCK

Capricor Therapeutics to Present at the 2025 Piper Sandler Virtual Cardio Day

01 Apr 2025 09:00:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

19 Mar 2025 16:05:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Announces Positive Data Demonstrating Long-Term Efficacy of Deramiocel for the Treatment of Duchenne Muscular Dystrophy

17 Mar 2025 09:25:00 By Nasdaq GlobeNewswire

Capricor Therapeutics to Present Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Update on March 19

11 Mar 2025 09:00:00 By Nasdaq GlobeNewswire

Capricor Therapeutics to Present at Leerink’s Global Healthcare Conference 2025

07 Mar 2025 09:25:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Announces FDA Acceptance and Priority Review of its Biologics License Application for Deramiocel to Treat Duchenne Muscular Dystrophy

04 Mar 2025 07:00:00 By Nasdaq GlobeNewswire

Capricor Therapeutics to Participate in Upcoming Investor Conferences

10 Feb 2025 09:00:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy

02 Jan 2025 09:15:00 By Nasdaq GlobeNewswire

Capricor Therapeutics to Present at Upcoming Investor Conferences

02 Dec 2024 16:15:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Granted Orphan Drug and ATMP Status for Deramiocel by European Medicines Agency

20 Nov 2024 09:00:01 By Nasdaq GlobeNewswire

Capricor Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

13 Nov 2024 16:01:00 By Nasdaq GlobeNewswire

Capricor Therapeutics to Present Exosome Platform Updates at 2024 American Association of Extracellular Vesicles Annual Meeting

12 Nov 2024 09:00:01 By Nasdaq GlobeNewswire

Capricor Therapeutics to Present Third Quarter 2024 Financial Results and Recent Corporate Update on November 13

05 Nov 2024 09:00:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Announces Closing of Underwritten Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

18 Oct 2024 16:01:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Announces Pricing of Approximately $75 Million Public Offering of Common Stock

17 Oct 2024 06:00:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Announces Proposed Public Offering of Common Stock

16 Oct 2024 16:17:48 By Nasdaq GlobeNewswire

NetDania - New 12 months High: CAPRICOR THERAPEUTICS INC. - COMMON STOCK

15 Oct 2024 12:27:21 By NetDania Notify

Capricor Therapeutics Announces Positive Long-Term Data from HOPE-2 OLE Study in Duchenne Muscular Dystrophy at 2024 World Muscle Society Congress

11 Oct 2024 09:15:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Announces Initiation of Rolling Submission of Biologics License Application (BLA) with U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy

09 Oct 2024 09:15:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: CAPRICOR THERAPEUTICS INC. - COMMON STOCK

04 Oct 2024 09:47:23 By NetDania Notify